Alogliptin Tablet, Film Coated
Product Images NDC 71610-661

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Alogliptin (NDC 71610-661). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle Label 12.5 mg (71610 0661 09)

Label for Alogliptin 12.5 mg film-coated tablets, containing 9000 tablets. The label includes storage instructions to keep between 20-25 degrees Celsius and dispense in a tight, light-resistant container. It is labeled as prescription-only with the manufacturer Aphena Pharma Solutions - Tennessee, LLC, located in Cookeville, TN. The National Drug Code (NDC) is 71610-0661.*

FDA Label Image

Aphena Pharma Solutions (TN)

FDA Label Image

Chemical Structure (Alogliptin 01)

Chemical structure of Alogliptin, shown with its molecular components and configuration, including a phenyl group and cyanide functional groups as part of its chemical makeup.*

FDA Label Image

Figure 1 (Alogliptin 02)

A clinical pharmacokinetic interaction chart for Alogliptin showing the ratio of Alogliptin combined with various coadministered drugs versus the coadministered drugs alone. The chart includes data points with confidence intervals for AUC and Cmax values under different substrate categories (Renally Excreted, CYP1A2, CYP2C8, CYP2C9, CYP2D6, CYP3A4, Pgp Substrate). The right column provides dosing recommendations, all stating no dose adjustment necessary.*

FDA Label Image

Figure 2 (Alogliptin 03)

A forest plot chart showing the pharmacokinetic (PK) effects of coadministered drugs on Alogliptin, including AUC and Cmax ratios with 90% confidence intervals. The chart compares Alogliptin alone versus combined with drugs affecting renal excretion, CYP2C8/9, CYP3A4, and Pgp pathways, with recommendations indicating no dose adjustments needed for any combinations.*

FDA Label Image

Figure 3 (Alogliptin 04)

A bar chart showing least squares mean change in A1C (%) for different treatments including placebo, Alogliptin at 25 mg, Pioglitazone at 15 mg, 30 mg, and 45 mg, and combinations of Alogliptin 25 mg with Pioglitazone at 15 mg, 30 mg, and 45 mg. The chart compares baseline mean A1C values and illustrates reductions in A1C across these treatments with statistical significance indicated for combination therapies.*

FDA Label Image

Figure 4 (Alogliptin 05)

A Kaplan-Meier cumulative event probability graph comparing Placebo (P) and NESINA (N) treatments over 30 months from randomization, showing event rates on the vertical axis and time in months on the horizontal axis. The graph includes numbers at risk for both groups at specific time points and displays a hazard ratio with 98% confidence interval.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.